Category: biostatistics

  • Private equity firms play ‘pass the Parexel’ with $8.5bn handover deal

    Four years after being taken private, Parexel has been sold again, with Goldman Sachs’ private equity arm and EQT paying $8.5 billion to claim ownership of the contract research organisation. The handover comes four years after Pamplona Capital Management bought the company for around $5 billion, and just a few weeks after lab tech company […]